Long-Term Effects of Bariatric Surgery on Type 2 Diabetes: Mechanisms, Outcomes, and Clinical Implications: A Focused Review

Metabolic/bariatric surgery is an effective intervention for people with obesity and type 2 diabetes mellitus (T2DM), with benefits extending beyond weight loss. This focused review examines long-term glycemic outcomes after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), one-anastomosis gastric bypass (OAGB), and adjustable gastric banding (AGB). Because reported remission depends on glycated hemoglobin thresholds, medication rules, and follow-up duration, we distinguish durable glycemic improvement from consensus-defined remission. We compare procedure-specific evidence and discuss adiposity, insulin sensitivity, pancreatic β-cell function, incretin hormones, bile acid signaling, and gut microbiota within an integrated intestine-liver-pancreas axis. RYGB and OAGB often show strong metabolic effects, but no operation is universally superior; procedure selection must balance efficacy against reflux, nutritional deficiencies, dumping, postbariatric hypoglycemia, and revisional needs. Current recommendations support considering surgery for eligible adults with T2DM and obesity. Lifelong multidisciplinary follow-up is required for glycemia, micronutrients, bone health, gastrointestinal symptoms, hypoglycemia, and weight recurrence. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 therapies may serve as alternatives, bridges, or postoperative adjuncts, although post-surgical evidence remains limited. Harmonized endpoints and prospective comparative studies are needed to improve individualized care.